Van Lanschot Kempen Logo
  • Home
  • Solutions
  • News & knowledge
  • About us

Newron Pharmaceuticals

Newron Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system and pain.
  • Placement of 2,000,000 new shares, representing 12.6% of Newron’s pre-deal outstanding share capital
  • Issue price of CHF 13.50 per share resulting in gross proceeds of CHF 27.0 million
  • Strong indications of interest were received during a market sounding exercise prior to transaction launch
  • The accelerated book-building process generated strong demand from US and European Life Sciences specialist and generalist investors, resulting in a multiple times oversubscribed order book
  • Transaction proceeds will be used for the company’s operations, research programs and the development of the company’s current and future pipeline products with a focus on its schizophrenia drug Evenamide
  • Kempen acted as Joint Global Coordinator and Joint Bookrunner in this transaction


Fully focused on your future

Private Banking

  • Offices
  • Business professionals
  • Executives
  • Doctors
  • Entrepreneurs
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions

Investment Management

Investment Banking

© Van Lanschot Kempen 2023
Privacy & cookies